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Background: Humans and dogs are affected by squamous cell carcinomas of the oral cavity (OSCC) in a
considerably high frequency. The high mobility group A2 (HMGA2) protein was found to be highly expressed in
human OSCC and its expression was suggested to act as a useful predictive and prognostic tool in clinical
management of oral carcinomas. Herein the expression of HMGA2 and its sister gene HMGA1 were analysed within
human and canine OSCC samples. Additionally, the HMGA negatively regulating miRNAs of the let-7 family as well
as the let-7 regulating gene Lin28 were also comparatively analysed. Deregulations of either one of these members
could affect the progression of human and canine OSCC.
Methods: Expression levels of HMGA1, HMGA2, Lin28, let-7a and mir-98 were analysed via relative qPCR in primary
human and canine OSCC, thereof derived cell lines and non-neoplastic samples. Additionally, comparative HMGA2
protein expression was analysed by immunohistochemistry.
Results: In both species, a significant up-regulation of the HMGA2 gene was found within the neoplastic samples
while HMGA1 expression did not show significant deregulations. Comparative analyses showed down-regulation of
mir-98 in human samples and up-regulation of let-7a and mir-98 in canine neoplastic samples. HMGA2 immunostainings
showed higher intensities within the invasive front of the tumours than in the centre of the tumour in both species.
Conclusions: HMGA2 could potentially serve as tumour marker in both species while HMGA1 might play a minor role in
OSCC progression. Comparative studies indicate an inverse correlation of HMGA2 and mir-98 expression in human
samples whereas in dogs no such characteristic could be found.
Keywords: Squamous cell carcinoma, HMGA1, HMGA2, let-7, mir-98, Lin28, Animal model, Dogs, Comparative oncologyBackground
Oral cancer is the eighth most frequent cancer worldwide
with even higher frequencies in developing than in
developed countries [1]. Furthermore, men develop
twice as frequent oral cancer than women and more
than 95% of the carcinomas are of the squamous cell
type. The standard treatment consists of surgery and/or
radiation with additional chemotherapy in advanced stages
of the disease. Tobacco and alcohol are regarded as the* Correspondence: Ingo.Nolte@tiho-hannover.de
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article, unless otherwise stated.major risk factors for oral cancers but also infection with
Human Papilloma Virus (HPV) are associated with a
subset of head and neck cancers [2].
In dogs, oral cancer is the fourth most common cancer
overall [3]. Similarly to humans, male dogs have a 2.4 times
higher risk of developing oropharyngeal malignancies
compared to female dogs and the tumours are staged
similarly to those in humans but only 17-25% of the
carcinomas are of the squamous cell type [3]. The risk for
metastatic disease is site dependent with a higher
metastatic potential in caudal tongue and tonsils and
a lower metastatic rate in the rostral oral cavity [3].
Surgery and radiation are the most common treatmenttral Ltd. This is an Open Access article distributed under the terms of the
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or radiation therapy is reported to lie between 26–36
months [3]. In humans, surgery and radiation are also the
most common treatment modalities resulting in estimated
overall 5-years survival rates for cancers of the oral cavity/
pharynx and larynx between 58.3% and 64.5% [4-6].
Due to the heterogeneity of head and neck tumours with
different site specific prognosis and survival, the integration
of multiple selected prognostic tumour markers in
association with the histopathologic features is advocated
for risk assessment. The search for biomarkers includes
evaluation of tumour tissues and surrogate material by
molecular, genomic and phenotypic means [7].
The high mobility group (HMG) protein A family
consists of two members HMGA1 and HMGA2 encoding
thee major proteins: HMGA1a, HMGA1b, and HMGA2.
The expression of HMGA1 and HMGA2 is high during
embryogenesis and strongly reduced to very low, hardly
detectable levels in adult tissues [8]. Re-expression in adult
tissues was described in several human and canine neopla-
sias as cancers of the prostate and colorectum as well as
lymphomas and non-small cell lung cancer [8-10].
Concerning human oral carcinoma, analysis of HMGA2
expression was reported to be found significantly
over-expressed in carcinoma tissues when compared
to non neoplastic tissues [11]. Immunohistochemical
localisation showed that HMGA2 protein was localised at
the invasive front of oral carcinomas leading to the
conclusion that HMGA2 immunostaining could be a
prognostic determinant in stratifying patients into risk
groups [11]. Analysis of HMGA1a and HMGA1b
expression showed different findings reporting no sig-
nificant expression deregulations [11] and increased
expression in head and neck carcinomas, when compared
to healthy mucosa samples [12].
HMGA2 expression was shown to be partly regulated by
the let-7 miRNA family member mir-98 in head and neck
squamous cell carcinoma cell lines [13]. Studies analysing
HMGA and let-7 expression in retinoblastomas and
gastroenteropancreatic neuroendocrine tumors revealed
a HMGA over expression accompanied by a down-regulation
of let-7 [14,15].
Let-7 micro RNAs themselves are regulated post-
transcriptionally by the LIN28 and LIN28B proteins
encoded by the Lin28 gene [16-19]. Accordingly, over-
expression of Lin28 was found to be linked to a repression
of let-7 family miRNAs and a combined down-regulation
of let-7 and up-regulation of Lin28 was reported in human
neoplasias [20]. Interestingly a recent study analysing
OSCCs reported increased expression of Lin28a and
Lin28b.Thereby, the increased levels of Lin28b could be
associated with poor prognosis [21].
In summary, the Lin28 – let-7 –HMGA regulatory
pathway and deregulations of either one of these membersor of all involved proteins and miRNAs could have an
effect on the progression and pathogeneses of human
and canine OSCC. Thus, in our study we investigated
the expression levels of HMGA1, HMGA2, Lin28, let-7 a
and mir-98 via relative real time PCR in human and
canine non-neoplastic and tumour tissue samples and
human and canine cell lines which derived from primary
OSCCs.Methods
Tissue samples obtained from human patients
This study included human squamous cell carcinoma,
non neoplastic controls, and tumour derived cell line
samples which were obtained from 12 patients (9 male,
3 female, age 20–71 years) who underwent surgery at the
Department of Oral and Maxillofacial Surgery, Hannover
Medical School. Ethical approval and informed patient
consent was obtained for all patients. This study was
approved by the local ethics committee at the Hannover
Medical School (Ref No. 984–2011). No patients had
received preoperative chemotherapy or radiotherapy.
The tumours (patients 2–12) were staged according to
TNM staging system and were classified as follows:
patient 2- pT4apN1, patient 3- pT1pN0, patient 4- rpT0
rpN2b R2 M1, patient 5- pT3pN0, patient 6- pT4apN0,
patient 7- pT4apN1, patient 8- pT4apN2b, patient
9- pT4apN2c, patient 10- pT4apN2b, patient 11- pT2pN0,
and patient 12-pT4 pN0.Tissue samples obtained from canine patients
Seven canine tumour and two healthy control samples
(five female, four male) were used covering seven breeds:
Boxer, Fox Terrier, Irish Terrier, Landseer, Retriever,
Sheltie (n = 1 respectively), and three Mixed-breeds. Age
ranged between a half year and eleven years. Samples
derived from the maxilla (4), tongue (2), mandible (1),
palate (1), and pharynx (1). All tumours were analysed
immunohistologically. All diagnoses were cytologically
and histologically confirmed according to the WHO
Nomenclature. The tumours were staged and graded as
follows: patient 3- grade IV (poor) stage T3bN1bM0,
patient 4- grade I (well) stage T2aN0M0, patient 5- grade I
(well) stage T3bN1aM0, patient 6- grade I (well)
stage T3bN1bM0, patient 7- grade III (moderate) stage
T3bN1bM0, patient 8- grade I (well) stage T1aN1bM0,
patient 9- grade I (well) stage T2aN0M0. The non
neoplastic control samples were collected from clinically
unaltered tongue and palate tissues and the dogs were
euthanized due to oral squamous cell carcinoma unrelated
diseases. All samples were taken and provided by the
Small Animal Clinic, University of Veterinary Medicine,
Hannover, Germany according to the legislation of the
state of Lower Saxony, Germany.
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Due to the possibility to access fresh neoplastic material of
both species we decided to aim at an establishment of
OSCC cell lines as tools for further experimental
approaches. The successful establishment of new cell lines
allowed us to compare the gene expression patterns of the
neoplastic primary tissues and the cell lines of both species.
The respective human and canine tumour samples were
verified to be squamous cell carcinomas by routine histo-
pathologic characterisation. The samples were analysed by
either a human or veterinary pathologist respectively. Two
human cell lines were generated from freshly isolated
squamous cell carcinoma biopsies derived from patient 4
and patient 12 (tumour staging see above). Single cell
suspensions were prepared with a gentleMACS™ tissue
dissociator (Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany). Samples were cut into small pieces of approxi-
mately 5 mm, transferred to a C Tube (Miltenyi Biotec
GmbH, Bergisch Gladbach, Germany) containing 5 ml
Dulbecco’s modified eagle medium (DMEM PAA, Pasching,
Austria) and subjected to the first homogenisation step. After
the addition of 1500 Units collagenase I (Cell Systems, St.
Katharinen, Germany) and 0,5 mg neutral peptidase (Cell
Systems, St. Katharinen, Germany), samples were incubated
for 40 min at 37°C. Digested samples were subjected to a
second homogenisation step followed by removal of tissue
debris using a 70 μM cell strainer (BD Biosciences,
Heidelberg, Germany). The cells were washed twice with
culture medium (DMEM, 10% fetal calf serum, 20 mM
Hepes, 1000 IU/ml penicillin and 0.1 mg/ml streptomycin;
all PAA, Pasching, Austria) and plated on 100 mm cell
culture dishes (Greiner, Frickenhausen, Germany) with
DMEM and incubated at 37 C and 5% CO2 until confluent.
The canine cell line was generated from a freshly isolated
oral squamous cell carcinoma biopsy. Due to the limited
amount of bioptic material this sample was not used in the
primary tissue screenings. The tumour tissue sample was
cut into small pieces with a sterile scalpel and treated with
collagenase (0.26%) for 2 hours at 37°C. The dissociated
cells were transferred into a sterile 10 ml tube and
centrifuged for 10 min at 1000*g. After centrifugation
the supernatant was discarded and the resuspended cell
pellet transferred into a sterile flask and incubated in 5 ml
culture medium (Medium 199 (Invitrogen, Frankfurt,
Germany), 10% fetal calf serum (PAA, Pasching, Austria)
200 U/ml penicillin and 200 ng/ml streptomycin
(Biochrom, Berlin, Germany) and incubated at 37°C
and 5% CO2 until confluent.
Homogenisation of tissue samples and cell lysates of
cultured cells
Tissue samples were homogenised using the stainless steel-
beads and Qiagen-TissueLyser II homogeniser method
accordingly to the manufacturer’s instructions (Qiagen,Hilden, Germany). Lysates of cultured cells were homoge-
nised with QIAshredder columns accordingly to the manu-
facturer’s protocol (Qiagen, Hilden, Germany).
RNA isolation and cDNA syntheses
RNA from tissue samples and cultured cells was isolated
using the RNeasy Mini Kit according to the manufacturer’s
instructions (Qiagen, Hilden, Germany). On-column DNase
digestion was performed with the RNase-Free DNase
set (Qiagen, Hilden, Germany). cDNA syntheses was
performed using 250 ng RNA and the QuantiTect Reverse
Transcription Kit following the manufacturer’s protocol
(Qiagen, Hilden, Germany).
Furthermore, total RNA including small RNAs like
miRNAs was isolated using the mirVana miRNA Isolation
Kit according to the manufacturer’s instructions (Ambion,
Applied Biosystems, Darmstadt, Germany). The respective
cDNA syntheses were performed using 100 ng total RNA
of each sample and the TaqMan MicroRNA Reverse
Transcription Kit following the manufacturer’s protocol
(Applied Biosystems, Darmstadt, Germany).
HMGA1, HMGA2, Lin28, GUSB and HPRT real time PCR
Relative quantification real time PCRs for both species
were carried out using the Eppendorf Mastercycler ep
realplex real-time PCR System (Eppendorf AG, Hamburg,
Germany).
For analysis of the human target genes, 2 μl of each
cDNA was amplified in a total volume of 25 μl using
universal PCR Mastermix and commercially purchased
TaqMan gene Expression Assays (HMGA1– Assay ID:
Hs00600784_g1; HMGA2– Assay ID: Hs00971724_m1;
Lin28A- Assay ID: Hs04189307_g1; HPRT- Assay ID:
Hs02800695_m1; GUSB- Assay ID: Hs99999808_m1;
(Applied Biosystems, Darmstadt, Germany)).
For analysis of canine target genes, 2 μl of each
cDNA was amplified using universal PCR Mastermix,
self-designed TaqMan based Assays ([9,22] (canine
HMGA1 (NM_001003387)- forward primer: 5′ ACCC
AGTGAAGTGCCAACACCTAA 3′, reverse primer:
5′ CCTCCTTCTCCAGTTTTTTGGGTCT 3′, probe:
5′ 6-FAM-AGGGTGCTGCCAAGACCCGGAAAACT
ACCA-TAMRA 3′; canine HMGA2 (DQ316099)- forward
primer: 5′ AGTCCCTCCAAAGCAGCTCAAAAG 3′,
reverse primer: 5′ GCCATTTCCTAGGTCTGCCTC
3′, probe: 5′ 6-FAM-CGCCCACTACTATGCCATCGT
GTG-TAMRA 3′; canine HPRT (NM_001003357)- forward
primer: 5′CCTTCTGCAGGAGAACCT 3′, reverse primer:
5′TCATCACTAATCACGACGCT 3′, probe: 5′6-FAM-
CCTCCTGTTCAGGCTGCCGTCA-TAMRA 3′; canine
GUSB (NM_001003191)- forward primer: 5′ TGGTGCT
GAGGATTGGCA 3′, reverse primer: 5′ CTGCCACATG
GACCCCATTC 3′, probe: 5′ 6-FAM-CGCCCACTA
CTATGCCATCGTGTG-TAMRA 3′) and commercially
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ID: Cf02725509_g1 (Applied Biosystems, Darmstadt,
Germany)).
The canine and human HMGA1 qPCR assays detected
both splicing variants (HMGA1a and HMGA1b) simultan-
eously. PCR conditions were as follows: 10 min at 95°C,
followed by 45 cycles with 15 s at 95°C and 1 min at 60°C.
All human and canine samples were measured in triplicate
and for each run non-template controls and non-reverse
transcriptase control reactions were included.Let-7a, mir-98 and RNU6B real-time PCR
Relative quantification of the human and canine let-7a,
mir-98 and RNU6B micro RNA transcript levels were
carried out using 1.33 μl of each cDNA amplified in a
total volume of 20 μl using TaqMan Universal PCR
Master Mix, No AmpErase UNG and TaqMan MicroRNA
assays for each gene (Let-7a- Assay ID: 000377;
mir-98- Assay ID: 000577; RNU6B- Assay ID: 001093
(Applied Biosystems, Darmstadt, Germany)).
PCR conditions were as follows: 10 min at 95°C,
followed by 45 cycles with 15 s at 95°C and 1 min at 60°C.
All samples were measured in triplicate and for each run
non-template controls and non-reverse transcriptase
control reactions were included.
A precedent efficiency analysis of the microRNA PCR
assays which were used in this study was performed by
applying the same template and dilution steps.Histological and immunohistochemical procedures
The formalin-fixed specimens were embedded in paraffin,
sectioned at 4 μm and routinely stained with haematoxylin
and eosin (H&E). Thereafter, polyclonal goat-anti human
HMGA2 (R&D Systems, Minneapolis, MN, USA) (1:400)
or mouse-anti human Ki-67 antibody (Dianova, Hamburg,
Germany) (1:100) was applied and allowed to incubate for
approximately 16–18 h. Sections were incubated with
biotin-conjugated horse antibody to goat IgG or goat
anti-mouse IgG (both Vector Laboratories, Burlingame,
CA, USA) (1:200) followed by ABC solution (Vectastain
Elite ABC kit, Vector). Tyramine amplification reaction
was performed according to the method of Adams
(1992) [23] for 15 min (only HMGA2). The chromogen
3-amino-9-ethyl-carbazol (AEC) (Biologo, Kronshagen,
Germany) was used for visualization followed by
counterstaining with Mayer’s haematoxylin. Negative
control sections were prepared by substituting the primary
antibody with PBS. For the scoring, the percentage of
carcinoma cells with intense red positive nuclear labelling
for HGMA2 was estimated by examining the centre of the
tumour and the invasive front (0: no expression; <25%
weak expression; 25-50% moderate expression; >50%:
strong expression).Statistical analysis
Statistical analysis of the relative real time PCR results
applying the Hypothesis Test was performed with the Rela-
tive expression software tool REST 2008, version 2.0.7 [24].
A p-value of <0.05 was considered statistically significant.
Results
Real time PCR expression analyses of HMGA1 and HMGA2
Human samples
HMGA1/GUSB expression levels varied from 0.225 to
1.47 within the control samples, and from 0.53 to 2.52
within the tumour samples. The HMGA1/HPRT expression
levels ranged from 0.21 to 2.02 within the control samples
and from 0.36 to 1.28 within the tumour samples (details
Figure 1A, B and Additional file 1: Table S1).
HMGA2/GUSB values ranged between 1 and 26.8 in the
control samples, 44.4 and 2330 in the tumour samples, and
319 and 1092 within the cell culture samples. HMGA2/
HPRT expression levels ranged between 1 and 31.1 within
the control group, 24.1 and 3778 within the tumour
group, and 226 to 561 within the cell culture samples
(Figure 1C, D and Additional file 1: Table S1).
Canine samples
HMGA1/GUSB expression levels varied from 1 to 1.67
within the non-neoplastic samples and from 0.152 to
1.69 within the neoplastic samples. HMGA1/HPRT
expression ranged from 1 to 1.31 in the non neoplastic
and 0.269 to 0.811 within the tumour samples (details
Figure 2A, B and Additional file 2: Table S2).
HMGA2/GUSB expression levels ranged from 0.383 to
1 within the non neoplastic samples and from 6.45 to 208
within the neoplastic samples. HMGA2/HPRT expression
ranged from 0.31 to 1 within the control group, and
from 3.69 to 80.7 within the tumours (Figure 2C, D
and Additional file 2: Table S2).
Statistical analyses of HMGA1 and HMGA2 expression
Human samples
HMGA1 was up-regulated when GUSB was used as
endogenous control gene within the tumour samples
(p = 0.0011) when compared to the non neoplastic
samples. HMGA2 was up-regulated when GUSB and
HPRT were used as endogenous control genes within
the tumour and cell line samples when compared to
the non neoplastic samples.
The respective p-values of the tumour and cell line
sample groups were p = 0.000 despite of the cell line
sample group within the HMGA2/GUSB real time PCR
showing a p-value of 0.001 (Figure 1).
Canine samples
HMGA1 was down-regulated when HPRT was used as
endogenous control gene within the tumour samples
Figure 1 Expression analyses of HMGA1 and HMGA2 in human OSCC. The study included 10 non neoplastic control samples (green columns)
and 10 tumour samples (red columns). A: relative HMGA1/GUSB real time PCR. B: relative HMGA1/HPRT real time PCR. C: relative HMGA2/GUSB real time
PCR. D: relative HMGA2/HPRT real time PCR. Statistical analysis was performed applying the Hypothesis Test using REST 2008 (version 2.0.7.). * indicates
a statistical significant expression deregulation of the HMGA genes when compared to non neoplastic control group; p-value is displayed next to *.
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samples. HMGA2 was up-regulated when GUSB and
HPRT were used as endogenous control genes within the
tumour samples when compared to the non neoplastic con-
trols. The analysed p-values were p = 0.002 and p = 0.003
within the HMGA2/GUSB and HMGA2/HPRT real time
PCRs respectively (Figure 2).
Immunohistochemistry
Human tumour sections
In the sections of patients 4 and 5 positive nuclear staining
for HMGA2 was detected in the tumour cells that were
located in the centre and/or the invasive front of the
tumours (Figure 3A-C). The percentages of labelled
tumour cells located in the centre were as follows: patient
4 – 30%, patient 5- 80%. Staining intensities of HMGA2 of
tumour cells located at the invasive front were as follows:
patient 4 – moderate (2+), patient 5 – strong (3+). The
remaining analysed sections of patients analysed did not
show positive staining for HMGA2.
Canine tumour sections
In all sections positive nuclear staining for HMGA2 was
detected in the tumour cells that were located in thecentre and/or at the invasive front of the tumours as
well (Figure 4). The percentages of labelled tumour
cells located in the centre were as follows: patients 3,
4, 7, 8 – 25-50% respectively. Patients 5, 6 and 9 - <25%
respectively. The percentages of labelled tumour cells
located at the invasive front were as follows: patient
3, 5, 6, 8 – 25-50%, patient 4, 7 and 9 - >50%, respectively.
Except the cases of patients 3 and 8, higher percentages of
positive nuclei were found at the invasive front of the
tumours. The percentages of Ki-67 labelled tumour
cells at the invasive front varied between 36% and
68%. In the decalcified sample from patient 6, no Ki-67
labelling was seen.
Comparative expression analyses of HMGA2, Lin28, let-7a
and mir-98
Human samples
Relative HMGA2/HPRT expression levels ranged from 1 to
4.61 within the non neoplastic samples, from 5.92 to 141
within the neoplastic samples and from 22.2 to 55.1 within
the cell line samples (Figure 5A, Additional file 3: Table S3).
Lin28/HPRT expression varied between 0 and 4.65
within the non neoplastic samples, from 0 to 27.5
within the neoplastic samples and from 1.03 to 4.87
Figure 2 Expression analyses of HMGA1 and HMGA2 in canine OSCC. The study included 2 non neoplastic control samples (green columns) and
7 tumour samples (red columns). A: relative HMGA1/GUSB real time PCR. B: relative HMGA1/HPRT real time PCR. C: relative HMGA2/GUSB real time PCR.
D: relative HMGA2/HPRT real time PCR. Statistical analysis was performed applying the Hypothesis Test using REST 2008 (version 2.0.7.). * indicates a
statistical significant expression deregulation of the HMGA genes when compared to non neoplastic control group; p-value is displayed next to *.
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Table S3).
let-7a/RNU6B expression ranged from 1 to 2.76 within
the non neoplastic samples, from 1.14 to 3.42 within the
neoplastic samples and from 1.11 to 2.33 within the cell
lines (Figure 5C, Additional file 3: Table S3).
mir-98/RNU6B expression ranged from 1 to 2.28
within the non neoplastic samples, from 0.91 to 7.22
within the neoplastic and from 0.65 to 1.05 within the
cell lines (Figure 5D, Additional file 3: Table S3).Figure 3 HMGA2 immunohistochemistry in human OSCC. Immunolabellin
(C). In the tumour centre (B) lower numbers of tumour cells with nuclear imm
(C). The invasive front shows numerous tumour cells exhibiting intense nucleaCanine samples
HMGA2/HPRT expression ranged from 1 to 1.19 within
the non neoplastic samples, from 3.09 to 178 within the
neoplastic samples and from 242 to 270 within the cell
line (Figure 6A, Additional file 4: Table S4).
Lin28/HPRT expression ranged between 0.02 and 1
within the non neoplastic samples, between 0 and 6.97
within the neoplastic samples, and between 0 and
0.03 within the cell line (Figure 6B, Additional file 4:
Table S4).g of a human tumour: overview (A), tumour centre (B) and invasive front
unolabelling are present when compared to the respective invasive front
r immunolabelling of HMGA2. Magnification: (A) 50x, (B) and (C) 200x.
Figure 4 HMGA2 immunohistochemistry in canine OSCC. Immunolabelling of a canine tumour grade II: overview (A), tumour centre (B) and
invasive front (C). HMGA2 staining in the tumour centre (B) revealed approx. 25% tumour cells with nuclear immunolabelling while cells at the
invasive front showed approx. 50% staining (C). Magnification: (A) 100x, (B) and (C) 200x.
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within the non neoplastic samples, from 0.84 to 7.36 within
the neoplastic samples and from 5.6 to 11.7 within the cell
line samples (Figure 6C, Additional file 4: Table S4).
Mir-98/RNU6B expression ranged from 1 to 3.8 within
the non neoplastic samples, from 3.93 to 6.97 within the
neoplastic samples and from 4.06 to 5.18 within the cell
line (Figure 6D, Additional file 4: Table S4).Non Neoplastic Control Sample Neoplastic Sample Cell Line, 























































































































































































Figure 5 Comparative expression analyses of the HMGA2 and Lin28 g
study included 5 non neoplastic control samples (green columns), 6 tumour s
A: relative HMGA2/HPRT real time PCR. B: relative Lin28/HPRT real time PCR. C:
PCR. Statistical analysis of the relative real time PCR results (Hypothesis Test) w
considered statistically significant. * indicates a statistical significant expression
compared to non neoplastic control group; p-value is displayed next to *.Statistical analyses of comparative HMGA2, Lin28, let-7a
and mir-98 expression
Human samples
HMGA2 was up-regulated when HPRT was used as
endogenous control gene within the tumour (p = 0.002)
and cell line samples (p = 0.024) when compared to
the non neoplastic samples (Figure 5A). mir-98 was
down-regulated when RNU6B was used as endogenousStatistically Significant Expression Deregulation OSCC Derived
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Figure 6 Comparative expression analyses of the HMGA2 and Lin28 genes and the let-7a and mir-98 miRNAs in canine OSCC. The study
included 2 non neoplastic control samples (green columns), 7 tumour samples (red columns) and 2 cell line derived samples (brown columns)
which derived from patients 1–10. A: relative HMGA2/HPRT real time PCR. B: relative Lin28/HPRT real time PCR. C: relative let-7a/RNU6B real time
PCR. D: relative mir-98/RNU6B real time PCR. Statistical analysis of the relative real time PCR results (Hypothesis Test) was performed with REST
2008 software tool. A p-value of <0.05 was considered statistically significant. * indicates a statistical significant expression deregulation of HMGA2
and/or Lin28 and/or let-7a and/or mir-98 when compared to non neoplastic control group; p-value is displayed next to *.
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pared to the non neoplastic control samples (Figure 5D).
Canine samples
HMGA2 was up-regulated when HPRT was used as
endogenous control gene within the tumour (p = 0.032) and
cell line samples (p = 0.000) when compared to the non
neoplastic samples (Figure 6A). let7-a was up-regulated
when RNU6B was used as endogenous control within
the cell lines samples (p = 0.000) when compared to the
non neoplastic control samples (Figure 6C). mir-98
was up-regulated when RNU6B was used as endogen-
ous control within the tumour samples (p = 0.000)
when compared to the non neoplastic control samples
(Figure 6D).
Discussion
The evaluation of the HMGA gene expression in the
analysed human and canine neoplasias showed con-
sistent expression in both species. Whereas HMGA2
was found to be strongly upregulated in the primary
samples as well as in the analysed cell lines the sis-
ter gene HMGA1 showed expression variation ran-
ging from two to three fold. Thus, herein HMGA2expression shows potential marker characteristics in
both species whereas HMGA1 misses the required
characteristics.
Previous studies analysing the HMGA1 expression in
human head and neck cancers reported contradictory
results, showing no statistical significant deregulations
as well as increased expression of HMGA1 in OSCC
[11,12], matching our results in both species. The
herein characterised high HMGA2 expression in the
neoplastic samples of both species, affirms the findings by
Miyazawa et al. [11] reporting HMGA2 over-expression of
84-315-fold in analysed carcinoma tissues when compared
to non neoplastic tissues [11].
HMGA2 was found to be expressed at the invasive front
of oral carcinomas leading to the conclusion that –in
contrast to HMGA1- HMGA2 immunostaining could
be a potential prognostic determinant in stratifying
patients into risk groups [11]. Further, multivariate risk
factor analysis demonstrated that HMGA2 expression
was found to be a significant independent predictor
of death of carcinoma and as an independent prognostic
marker for disease-specific overall survival [11]. Contrary
to this, HMGA1 expression was also reported to be
increased in head and neck carcinomas analysed via
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when compared to healthy mucosa samples [12].
The herein reported immunohistochemical staining in
human sections showed positive HMGA2 staining
within the centre and the invasive front of the tumour
sections in only two patients. In contrast, in all canine
samples the immunohistochemichal staining showed
positive signals for HMGA2. Thereby, with exception of
two cases, the percentages of positive nuclei for HMGA2
were higher at the invasive front of the tumour sections
than in the centre of the tumours. Similarly, Miyazawa et al.
reported a negligible HMGA2 staining in the central area of
the human carcinoma tissues whereas it was ectopically
expressed at the invasive front [11]. In general, most of the
oral cancer deaths result from local invasion and distant
metastasis. At the invasive front, the carcinoma cells gain
the characteristics similar to mesenchymal cells due to
epithelial-mesenchymal transition (EMT) where cells
switch from a polarised epithelial phenotype to a motile
mesenchymal phenotype and facilitate tumour invasion
[25,26]. The role of HMGA2, which is a mesenchym-
specific factor was thus strongly correlated with poor
differentiation, invasion and metastasis of oral cancer
[11,25,26]. Our immunohistochemical findings in canine
OSCC are comparable with the findings seen in human
OSCC supporting the data discussing a possible role of
HMGA2 as a factor promoting cell proliferation and
motility at the invasive front in canine oral cancer.
In our study, mir-98 was significantly down-regulated
in the analysed OSCC cell lines describing an inverse
expression pattern of HMGA2 and mir-98. As this
observation is limited to qPCR assays, a definitive
statement can hardly be drawn at this point without
further transcriptomic analyses. However, interestingly
Hammond et al. postulated a linear pathway from
Lin28 to let-7 to HMGA2 [27]. In embryonic stem cells
Lin28 expression is highly leading to the inhibition of let-7
microRNAs processing steps. These low let-7 microRNAs
levels allow a high expression of their usually repressed
target genes as HMGA2. Accordingly, HMGA2 expression
increases as observed in embryonic stem cells and in
several cancers [27]. Our results are in agreement with a
study by Hebert et al. reporting that HMGA2 expression is
partly regulated by mir-98 in head and neck squamous cell
carcinoma cell lines [13]. The let-7a miRNA was reported
to be down-regulated in head and neck cancer tissues
and the expression levels were significantly reduced in
metastatic tissues when compared to primary tumours.
Thereby, a high let-7a score was found to be associ-
ated with early T-stage and low lymph node metasta-
sis and early pathological stage [28]. Additionally, in
human oesophageal squamous cell carcinoma, an
inverse transcription of let-7 and HMGA2 was reported
[29]. However, the authors did not mention whichmembers of the let-7 family were analysed and thus it
cannot be excluded that let-7a and mir-98 were not
analysed within the study.
We performed the statistical analysis of the different
real time PCRs for all samples as groups with no regard
to the single patients. The human patients 4 and 7
could provide real time data for both sample types as
non-neoplastic and neoplastic material was existent.
Expression of HMGA2 and Lin28 were higher in the
neoplastic samples while let-7a and mir-98 expression
were higher in the non-neoplastic samples. Here, an
inverse correlation of the expression of HMGA2 and
Lin28 and let-7a and mir-98 could be detected in the
tumour samples when compared to healthy tissue.
These results strongly fortify the described Lin28 to
let-7 to HMGA2 axis hypothesis drawn by Hammond et al.
[27]. Further, increased levels of Lin28b could be associated
with poor prognosis OSCCs [21]. Nevertheless, it must be
considered that the statistical analyses of our real time
PCRs did not confirm a significant down-regulation
of let-7a and a simultaneous over-expression of Lin28
when all samples were analysed as groups. In general, an
inverse correlation of let-7 and HMGA2 is a frequent
finding in many types of human neoplasias. Nevertheless,
in adipocytic tumours, despite of some individual let-7
miRNAs, no global correlation between expression of
let-7 members and HMGA2 were detected [30]. Similarly,
our results regarding let-7a expression suggest, that a
decrease in let-7a expression does not appear to be main
mechanism accounting for HMGA2 deregulation. Hereby,
let-7a is likely to be involved in the pathogenesis of OSCC
probably through mechanisms other than those expected.
Nevertheless, our results provide a first trend of
comparative expression of HMGA2, Lin28, let-7a and
mir-98 in OSCC and must be verified in a larger set
of tissue control and tumour samples to determine if
there is an inverse correlation of expression between
these genes and if there is a potential link to disease
progression.
Comparative expression analyses of HMGA2, Lin28,
let-7a and mir-98 in canine samples showed a statistical
significant over expression of HMGA2 in neoplastic
samples confirming our precedent results. Besides this,
the study revealed different results when compared to
the results made in the comparative expression study in
human samples. Let-7a was over expressed within the
cell line samples while mir-98 was over expressed in
the tumour samples. These findings do not indicate a
negative correlation of expression of HMGA2 and Lin28
and the let-7a and mir-98. Thus, analysis of more control
and tumour samples would be required to improve the
power of the study and additional microRNAs should
be taken into account, which might be involved in the
progression of canine OSCC.
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survival time was not focussed in this study due to the
limited number of analysed cases. Additionally, regarding
canine patients, an accurate follow up is often hindered
by the fact that veterinary patients are frequently not
represented at the academic institution as owners follow
treatment at local veterinarians. Furthermore, central
cancer register for canine patients, as present for human
cancer patients, does not exist. However, due to the
similarities in canine and human cancer presentation,
as reported herein, basic research and the development of
clinical regimens in either of the species provide valuable
solid data for the respective counterpart.Conclusion
In conclusion, the comparative expression study analysing
a possible inverse correlation between HMGA2 and Lin28
and let-7 members in OSCC revealed a down-regulation
of mir-98 with a simultaneous HMGA2 over expression in
human OSCC cell line samples. In contrast to the findings
made in human samples, comparative analyses in canine
showed different expression patterns. Despite the HMGA2
over-expression in neoplastic samples, the miRNAs let-7a
and mir-98 were found to be up-regulated. Consequently,
in canine OSCC further factors might be involved in the
progression neoplasia when compared to the analysed
human OSCCs. Furthermore the miRNAs analysed herein
might not reflect the main factors involved in deregulation
of HMGA2 in canine OSCC.Additional files
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